Backstrom Jay T. - 13 Nov 2025 Form 4 Insider Report for LAVA Therapeutics NV (LVTX)

Reporting relationship: Director
Issuer ticker: LVTX
Reported as of: 13 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Nov 2025, 16:30:14 UTC
Prior SEC filing: 10 Jul 2025
Next SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Amy Garabedian, Attorney-in-Fact

Key filing fact

Backstrom Jay T. filed Form 4 for LAVA Therapeutics NV (LVTX) on 17 Nov 2025.

Key facts

This page summarizes Backstrom Jay T.'s Form 4 filing for LAVA Therapeutics NV (LVTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Nov 2025, 16:30.

Change

Previous filing in this sequence was filed on 10 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796398 Primary reporting owner

Backstrom Jay T.

Relationship: Director
Address: C/O LAVA THERAPEUTICS N.V., YALELAAN 62, UTRECHT, NETHERLANDS
Signature: /s/ Amy Garabedian, Attorney-in-Fact
Signature date: 17 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LVTX transaction Derivative

Share Options (Right to Buy)

Disposed to Issuer

Transaction value: $0
Shares: -33,390
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 13 Nov 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 33,390
Exercise price: $0.9300
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Backstrom Jay T. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

This option was cancelled pursuant to that certain Purchase Agreement, dated August 3, 2025, by and between the Issuer and XOMA Royalty Corporation (as amended, the "Purchase Agreement") in exchange for cash and contingent value rights ("CVRs") (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to (i) the excess of $1.04 over the per share exercise price of such option multiplied by the total number of shares underlying such in option and (ii) one CVR per share underlying such in-the-money option.